W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Overcoming cellular senescence in human cancer pathogenesis
Thomas R. Yeager,Sandy DeVries,David F. Jarrard,Chinghai Kao,Stephen Y. Nakada,Timothy D. Moon,Reginald C. Bruskewitz,Walter M. Stadler,Lorraine F. Meisner,Kennedy W. Gilchrist,Michael A. Newton,Frederic M. Waldman,Catherine A. Reznikoff +12 more
TL;DR: Data from this study support a new model in which overcoming senescence plays a critical role in human cancer pathogenesis and requires at least two genetic changes that occur in several combinations that can include either p16 or pRb loss and at least one additional alteration, such as -8p21-pter.
Journal ArticleDOI
Urinary Nuclear Matrix Protein as a Marker for Transitional Cell Carcinoma of the Urinary Tract
Gennaro A. Carpinito,Walter M. Stadler,Joseph V. Briggman,Gerald W. Chodak,Paul Church,Donald L. Lamm,Paul H. Lange,Edward M. Messing,Robert M. Pasciak,George B. Reservitz,Robert N. Ross,Daniel B. Rukstalis,Michael F. Sarosdy,Mark S. Soloway,Robert P. Thiel,Nicholas J. Vogelzang,Cheryl L. Hayden +16 more
TL;DR: NMP22 is a promising urinary tumor marker for monitoring transitional cell carcinoma of the urinary tract and represents the basis for the development of assays with increased efficacy for the detection and treatment of cancer.
Journal ArticleDOI
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
Ronald M. Bukowski,Timothy Eisen,C. Szczylik,Walter M. Stadler,Ronit Simantov,M. Shan,J. Elting,Carol Peña,Bernard Escudier +8 more
TL;DR: Final OS differences did not reach prespecified O’Brien-Fleming statistical boundaries and are reported.
Journal ArticleDOI
Phase II Trial of PS-341 in Patients With Renal Cell Cancer: A University of Chicago Phase II Consortium Study
Nancy B. Davis,David A. Taber,Rafat Ansari,Christopher W. Ryan,Christopher George,Everett E. Vokes,Nicholas J. Vogelzang,Walter M. Stadler +7 more
TL;DR: Evidence is lacking for clinically significant activity of PS-341 in metastatic renal cell cancer, and insufficient biopsy and whole blood sample numbers preclude conclusions regarding proteasome inhibition within tumor.
Journal ArticleDOI
Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
Brian I. Rini,May Garrett,Bill Poland,Janice P. Dutcher,Olivier Rixe,George Wilding,Walter M. Stadler,Yazdi K. Pithavala,Sinil Kim,Jamal Tarazi,Robert J. Motzer +10 more
TL;DR: Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved for second-line therapy for advanced renal cell carcinoma (RCC) as mentioned in this paper.